Staphylococcal scalded skin syndrome is a toxin-mediated blistering skin disorder caused by exfoliative toxins A and B (ETA/ETB) produced by phage group II Staphylococcus aureus. It predominantly affects neonates and children <6 years due to immature renal clearance of the toxin and lack of neutralizing antibodies. [1-2] Annual incidence is ~7.67 per million U.S. children, with the highest rates in infants <2 years (~45 per million). [3] Pediatric mortality is low (~0.3%), but adult mortality ranges from 40–63% due to underlying comorbidities. [3-4]
1. History
- Onset: Abrupt prodrome of fever, irritability, malaise, and skin tenderness followed within 24–48 hours by erythema and blistering [1-2]
- Preceding infection: Ask about recent impetigo, conjunctivitis, sore throat, URI, otitis, wound/surgical site, or umbilical stump infection (neonates) [2][5]
- Skin pain: Exquisite skin tenderness is a hallmark — often out of proportion to visible findings early on [1]
- Progression: Erythema typically begins in skin folds (axillae, groin, neck) and periorificial areas → flaccid bullae → widespread desquamation in a head-to-toe direction [1-2]
- Oral intake: Decreased PO intake is common due to perioral crusting and pain [2]
- Medication history: Important to exclude drug-induced TEN (ask about recent sulfonamides, antibiotics, anticonvulsants) [6]
2. Alarm Features
- Hemodynamic instability or signs of sepsis — should broaden the differential away from SSSS [2]
- Extensive body surface area involvement with significant fluid losses
- Mucosal involvement (oral, genital) — suggests TEN rather than SSSS [6-7]
- Adults presenting with SSSS features — high mortality; search for underlying renal failure or immunosuppression [4]
- Neonates <1 month — higher risk of dehydration, temperature dysregulation, and secondary infection [5]
- Failure to improve within 36–48 hours of appropriate antibiotics [2]
3. Medications
- First-line: Beta-lactam antibiotics — IV cefazolin or oral cephalexin preferred over nafcillin/oxacillin (which cause phlebitis and require slow infusion) [2][8]
- MRSA coverage: Add vancomycin in high-MRSA-prevalence areas, history of MRSA colonization/furuncles, or failure to respond to initial therapy [2][5][9]
- Clindamycin: Despite theoretical anti-toxin effect, systematic review evidence shows it does not improve outcomes, and SSSS isolates have high clindamycin resistance rates (52–85%) — not recommended as first-line [2][5][8][10]
- Avoid corticosteroids — contraindicated in SSSS (immunosuppressive; may worsen infection)
- IVIG: Previously recommended but a recent study associates its use with prolonged hospitalization — not routinely recommended [4]
- Analgesics: Acetaminophen/ibuprofen for pain and fever; consider opioids for severe skin pain
4. Diet
- Perioral crusting and fissuring may limit oral intake — soft, bland foods and cool liquids are better tolerated
- Maintain adequate hydration; denuded skin leads to insensible fluid losses similar to burn patients
- IV fluid resuscitation for children unable to maintain oral intake [2]
- No specific long-term dietary modifications required
5. Review of Systems
- Constitutional: Fever, irritability, lethargy, poor feeding [2]
- Skin: Tenderness, erythema, peeling, blistering — ask about distribution and progression
- HEENT: Conjunctivitis, perioral crusting/fissures, sore throat, ear pain [2][5]
- GI: Decreased oral intake, perianal erythema/infection source
- Respiratory: Cough, rhinorrhea (preceding URI as source)
- GU: Perianal/perineal skin involvement
- Mucosal surfaces: Absence of true mucosal erosions helps distinguish from TEN [6]
6. Collateral History and Family History
- Daycare or household contacts with skin infections (impetigo, boils)
- Personal or family history of MRSA colonization or recurrent staphylococcal infections [2]
- Immunodeficiency in the family (relevant for adult SSSS or atypical presentations)
- Prior episodes of SSSS (recurrence is possible)
- Social context: Hygiene conditions, crowded living situations
7. Risk Factors
- Age <6 years (especially neonates and infants <2 years) — immature renal clearance and low anti-exfoliative toxin antibody titers [1][11]
- Preceding staphylococcal infection: impetigo, conjunctivitis, URI, wound infection [2]
- Atopic dermatitis (reported in 5–15% of cases) [2]
- Seasonal: Higher incidence in summer and autumn [3-4]
- Adults: Renal insufficiency, immunosuppression (HIV, malignancy, chemotherapy, organ transplant) [4][6]
- Female sex slightly more common; lower rates in Black children [3]
8. Differential Diagnosis
- Toxic epidermal necrolysis (TEN) — the most critical cannot-miss diagnosis. Distinguished by: drug exposure history, mucosal involvement, full-thickness epidermal necrosis on biopsy (subepidermal cleavage), and necrotic keratinocytes. SSSS shows superficial intraepidermal split at the granular layer [6-7][12]
- Bullous impetigo — localized form of the same toxin-mediated process; limited to site of infection rather than disseminated [6]
- Pemphigus foliaceus — autoimmune; also targets desmoglein 1 with similar superficial blistering but chronic course and positive DIF [6]
- Scarlet fever — sandpaper-like rash with pharyngitis; no bullae or Nikolsky sign
- Kawasaki disease — prolonged fever, conjunctival injection, mucositis, extremity changes; desquamation occurs later (convalescent phase)
- Thermal burns/child abuse — distribution pattern and history help distinguish
- Acute generalized exanthematous pustulosis (AGEP) — drug-related, subcorneal pustules [7]
- Stevens-Johnson syndrome — mucosal involvement, target lesions, drug-related [13]
9. Past Medical History
- Prior episodes of SSSS or bullous impetigo
- History of atopic dermatitis or eczema (skin barrier disruption)
- Recent wounds, surgical sites, or burns (portals of entry) [14]
- Immunodeficiency states (especially in adults or atypical presentations)
- Renal disease (impaired toxin clearance) [4]
- Neonates: birth history, umbilical stump care, nursery exposures
10. Physical Exam
- Vital signs: Usually within normal limits; tachycardia is the most common abnormality. Patients are typically NOT septic [2]
- Skin: Diffuse, tender erythema beginning in flexural folds → flaccid, thin-walled bullae → widespread superficial desquamation with a "scalded" appearance [1-2]
- Nikolsky sign: Positive — gentle lateral pressure on uninvolved skin causes the superficial epidermis to shear off [2]
- Periorificial findings: Crusting and radial fissuring around the mouth, nose, and eyes — classic and highly suggestive [2][15]
- Mucous membranes: Spared (unlike TEN) — this is a key distinguishing feature [6]
- Assess for primary infection source: Conjunctivae, nares, oropharynx, ears, umbilicus (neonates), perianal area, wounds [5]
- Estimate BSA involvement for fluid management planning
11. Lab Studies
- Routine labs (CBC, CMP, CRP) are largely non-specific and do not enhance diagnostic accuracy — a 2025 systematic review found they do not improve outcomes or inform care [2][8]
- Aerobic bacterial cultures from suspected foci of infection (conjunctiva, nasopharynx, perioral, perianal, wounds, umbilicus) — more likely to yield positive results than blood cultures [2][5]
- Blood cultures: Typically sterile in otherwise healthy children; routine blood cultures are not recommended as they may increase false-positive results [2]
- In adults or immunocompromised patients: blood cultures, renal function, and broader workup are warranted given higher mortality [4]
- If TEN is a concern: consider checking for lymphopenia (associated with SJS/TEN) [13]
12. Imaging
- No routine imaging is indicated for SSSS
- Chest X-ray only if concern for pneumonia (a feared complication) or respiratory distress [4]
- Imaging may be warranted to identify a deep-seated source of staphylococcal infection in atypical or adult cases
13. Special Tests
- Skin biopsy (frozen section): Gold standard for diagnosis but not required when clinical presentation is classic. Reveals split at the stratum granulosum (superficial, intraepidermal) with acantholysis [2][4][6]
- Nikolsky sign: Bedside clinical test — positive in SSSS [2]
- Dermoscopy: May show partially remaining epidermis with less leachate at fresh exfoliation sites; not yet validated in large studies [2]
- Exfoliative toxin assay: Can confirm ETA/ETB but not widely available or necessary for clinical management [14]
- D-test: For clindamycin susceptibility testing if clindamycin is being considered [8]
14. ECG
- Not routinely indicated in SSSS
- Consider ECG if there is concern for electrolyte derangements from significant fluid losses or if the differential includes Kawasaki disease or toxic shock syndrome
15. Assessment
- SSSS is a clinical diagnosis based on the characteristic triad of: tender erythroderma → flaccid bullae with positive Nikolsky sign → periorificial crusting/fissuring, in a young child with a preceding staphylococcal infection [1-2][8]
- Severity stratification:
- Mild: Localized erythema and desquamation, tolerating PO, stable vitals
- Moderate-severe: Widespread desquamation, significant BSA involvement, poor oral intake, fever
- Most pediatric patients are previously healthy with no significant PMH [2]
- Complications: Fluid loss/dehydration, temperature dysregulation, secondary skin infection, and rarely sepsis or pneumonia [4-5]
- Erythema typically improves within 36 hours of appropriate antibiotics; full resolution in 2–3 weeks without scarring [1-2]
16. Treatment Plan
Initial stabilization:
- IV access; assess hydration status and fluid resuscitation as needed (similar principles to burn management for significant BSA involvement) [2]
- Pain management — acetaminophen, ibuprofen; opioids for severe pain
- Minimize skin manipulation (avoid adhesive dressings, unnecessary handling)
Antibiotics:
- First-line: IV cefazolin (transition to oral cephalexin when improving) — preferred over nafcillin/oxacillin due to ease of administration and less phlebitis [2][8]
- If MRSA concern: IV vancomycin [2][5][9]
- Clindamycin is not recommended as first-line given lack of outcome benefit and high resistance rates [2][8]
- Transition to oral antibiotics when erythema is improving and patient is tolerating PO; complete a 7–10 day total course
Skin care:
- Bland emollients (e.g., petrolatum) to denuded areas [2]
- Gentle cleansing; avoid harsh soaps or topical antiseptics
- Non-adherent dressings if needed
Fluids:
17. Disposition
Admission criteria:
- Extensive skin involvement or significant BSA denudation
- Inability to maintain oral intake / dehydration
- Neonates or infants <3 months
- Systemic toxicity (high fever, tachycardia, lethargy)
- Need for IV antibiotics or fluid resuscitation
- Diagnostic uncertainty (concern for TEN)
- Mean hospital LOS is approximately 3.2 days [3]
Discharge criteria:
- Improving erythema (typically within 36 hours of antibiotics)
- Tolerating oral antibiotics and adequate PO intake
- Adequate pain control
- Reliable caregiver with clear return precautions
Specialist consultation:
- Dermatology: When diagnosis is uncertain or biopsy is needed to differentiate from TEN [6]
- Burn surgery: If extensive BSA involvement requiring specialized wound care
- Pediatric infectious disease: Refractory cases or MRSA concerns
18. Follow Up / Return Precautions
- Follow-up: Primary care or dermatology within 48–72 hours of discharge to reassess skin healing and antibiotic response
- Expected course: Desquamation continues for 10–14 days; complete healing in 2–3 weeks without scarring [1-2]
- Return immediately for: Worsening redness or skin peeling, new blistering, fever >38.5°C, decreased oral intake/urine output, increasing irritability or lethargy, signs of secondary infection (purulence, warmth, spreading erythema)
- Counseling: Reassure caregivers that SSSS heals without scarring in children with prompt treatment; emphasize completing the full antibiotic course; gentle skin care with bland emollients; avoid picking or rubbing peeling skin
References
1. Recognizing and Managing Staphylococcal Scalded Skin Syndrome in the Emergency Department. — Nguyen QD, Vu MN, Hebert AA. Pediatric Emergency Care. 2022.
2. Recognizing and Managing Staphylococcal Scalded Skin Syndrome in the Emergency Department. — Nguyen QD, Vu MN, Hebert AA. Pediatric Emergency Care. 2022.
3. Recognizing and Managing Staphylococcal Scalded Skin Syndrome in the Emergency Department. — Nguyen QD, Vu MN, Hebert AA. Pediatric Emergency Care. 2022.
4. Pediatric Staphylococcal Scalded Skin Syndrome: A Systematic Review of the Literature to Inform Work‐Up and Management. — Gray L, Hansen AM, Cipriano SD. Pediatric Dermatology. 2025.
5. Pediatric Staphylococcal Scalded Skin Syndrome: A Systematic Review of the Literature to Inform Work‐Up and Management. — Gray L, Hansen AM, Cipriano SD. Pediatric Dermatology. 2025.
6. Epidemiology of Staphylococcal Scalded Skin Syndrome in U.S. Children. — Staiman A, Hsu DY, Silverberg JI. The British Journal of Dermatology. 2018.
7. Epidemiology of Staphylococcal Scalded Skin Syndrome in U.S. Children. — Staiman A, Hsu DY, Silverberg JI. The British Journal of Dermatology. 2018.
8. Staphylococcal Scalded Skin Syndrome: Diagnosis and Management in Children and Adults. — Handler MZ, Schwartz RA. Journal of the European Academy of Dermatology and Venereology : JEADV. 2014.
9. Staphylococcal Scalded Skin Syndrome: Diagnosis and Management in Children and Adults. — Handler MZ, Schwartz RA. Journal of the European Academy of Dermatology and Venereology : JEADV. 2014.
10. Staphylococcal scalded skin syndrome: An epidemiological and clinical review of 84 cases. — Liy-Wong C, Pope E, Weinstein M, Lara-Corrales I. Pediatric Dermatology. 2021.
11. Staphylococcal scalded skin syndrome: An epidemiological and clinical review of 84 cases. — Liy-Wong C, Pope E, Weinstein M, Lara-Corrales I. Pediatric Dermatology. 2021.
12. Pemphigus, Bullous Impetigo, and the Staphylococcal Scalded-Skin Syndrome. — Stanley JR, Amagai M. The New England Journal of Medicine. 2006.
13. Pemphigus, Bullous Impetigo, and the Staphylococcal Scalded-Skin Syndrome. — Stanley JR, Amagai M. The New England Journal of Medicine. 2006.
14. Severe Adverse Cutaneous Reactions to Drugs. — Roujeau JC, Stern RS. The New England Journal of Medicine. 1994.
15. Severe Adverse Cutaneous Reactions to Drugs. — Roujeau JC, Stern RS. The New England Journal of Medicine. 1994.
16. Staphylococcal scalded skin syndrome: Clinical features, ancillary testing, and patient management. — Gray L, Olson J, Brintz BJ, Cipriano SD. Pediatric Dermatology. 2022.
17. Staphylococcal scalded skin syndrome: Clinical features, ancillary testing, and patient management. — Gray L, Olson J, Brintz BJ, Cipriano SD. Pediatric Dermatology. 2022.
18. Demographic characteristics, clinical features, and optimal management of hospitalized patients with staphylococcal scalded skin syndrome. — Vernali S, Blasiak RC, Morrell DS. Pediatric Dermatology. 2021.
19. Demographic characteristics, clinical features, and optimal management of hospitalized patients with staphylococcal scalded skin syndrome. — Vernali S, Blasiak RC, Morrell DS. Pediatric Dermatology. 2021.
20. Antibiotic sensitivity and clinical outcomes in staphylococcal scalded skin syndrome. — Wang Z, Feig JL, Mannschreck DB, Cohen BA. Pediatric Dermatology. 2020.
21. Antibiotic sensitivity and clinical outcomes in staphylococcal scalded skin syndrome. — Wang Z, Feig JL, Mannschreck DB, Cohen BA. Pediatric Dermatology. 2020.
22. Understanding Host's Response to Staphylococcal Scalded Skin syndrome. — Rouva G, Vergadi E, Krasagakis K, Galanakis E. Acta Paediatrica. 2025.
23. Understanding Host's Response to Staphylococcal Scalded Skin syndrome. — Rouva G, Vergadi E, Krasagakis K, Galanakis E. Acta Paediatrica. 2025.
24. Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions. — Orime M. Journal of Immunology Research. 2017.
25. Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions. — Orime M. Journal of Immunology Research. 2017.
26. Distinguishing Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis From Clinical Mimickers During Inpatient Dermatologic Consultation-a Retrospective Chart Review. — Weinkle A, Pettit C, Jani A, et al. Journal of the American Academy of Dermatology. 2019.
27. Distinguishing Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis From Clinical Mimickers During Inpatient Dermatologic Consultation-a Retrospective Chart Review. — Weinkle A, Pettit C, Jani A, et al. Journal of the American Academy of Dermatology. 2019.
28. Presentation and Management of Staphylococcal Scalded Skin Syndrome in a Child After a Burn Injury: A Case Report. — Pidgeon TE, D'Asta F, Ogboli M, Wilson Y. Journal of Burn Care & Research : Official Publication of the American Burn Association. 2020.
29. Presentation and Management of Staphylococcal Scalded Skin Syndrome in a Child After a Burn Injury: A Case Report. — Pidgeon TE, D'Asta F, Ogboli M, Wilson Y. Journal of Burn Care & Research : Official Publication of the American Burn Association. 2020.
30. Scaling and Periorificial Crusts in a Pediatric Patient. — Fayos-Gregori R, Mansilla-Polo M, Fernández GA, Botella-Estrada R. Infection. 2024.
31. Scaling and Periorificial Crusts in a Pediatric Patient. — Fayos-Gregori R, Mansilla-Polo M, Fernández GA, Botella-Estrada R. Infection. 2024.
32. Fast, Bedside Diagnosis of Toxic Epidermal Necrolysis Using Ex Vivo Confocal Laser Scanning Microscopy: A Retrospective Study. — Tonellotto L, Seremet T, Vernez M, Guenova E, Kuonen F. Journal of the European Academy of Dermatology and Venereology : JEADV. 2024.
33. Fast, Bedside Diagnosis of Toxic Epidermal Necrolysis Using Ex Vivo Confocal Laser Scanning Microscopy: A Retrospective Study. — Tonellotto L, Seremet T, Vernez M, Guenova E, Kuonen F. Journal of the European Academy of Dermatology and Venereology : JEADV. 2024.